CN105726638A - Lipid-lowering and liver-protecting composition and application thereof - Google Patents
Lipid-lowering and liver-protecting composition and application thereof Download PDFInfo
- Publication number
- CN105726638A CN105726638A CN201610245139.1A CN201610245139A CN105726638A CN 105726638 A CN105726638 A CN 105726638A CN 201610245139 A CN201610245139 A CN 201610245139A CN 105726638 A CN105726638 A CN 105726638A
- Authority
- CN
- China
- Prior art keywords
- group
- fat
- liver
- cortex mori
- radix astragali
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 66
- 239000009636 Huang Qi Substances 0.000 claims abstract description 58
- 208000010706 fatty liver disease Diseases 0.000 claims abstract description 23
- 231100000240 steatosis hepatitis Toxicity 0.000 claims abstract description 22
- 208000004930 Fatty Liver Diseases 0.000 claims abstract description 21
- 206010019708 Hepatic steatosis Diseases 0.000 claims abstract description 21
- 201000005577 familial hyperlipidemia Diseases 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 14
- 208000008589 Obesity Diseases 0.000 claims abstract description 12
- 235000020824 obesity Nutrition 0.000 claims abstract description 12
- 235000013305 food Nutrition 0.000 claims description 34
- 230000036541 health Effects 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 238000013461 design Methods 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 239000011347 resin Substances 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 15
- 229940079593 drug Drugs 0.000 abstract description 6
- 235000008708 Morus alba Nutrition 0.000 abstract description 3
- 240000000249 Morus alba Species 0.000 abstract description 3
- 235000010575 Pueraria lobata Nutrition 0.000 abstract description 3
- 244000046146 Pueraria lobata Species 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 69
- 239000003862 glucocorticoid Substances 0.000 description 59
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 50
- 241000700159 Rattus Species 0.000 description 43
- 239000008103 glucose Substances 0.000 description 35
- 235000012000 cholesterol Nutrition 0.000 description 34
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 33
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 32
- 210000004369 blood Anatomy 0.000 description 32
- 239000008280 blood Substances 0.000 description 32
- 150000002632 lipids Chemical class 0.000 description 31
- 238000012360 testing method Methods 0.000 description 27
- 230000006698 induction Effects 0.000 description 26
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 22
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 21
- 229960001052 streptozocin Drugs 0.000 description 21
- 108010007622 LDL Lipoproteins Proteins 0.000 description 20
- 102000007330 LDL Lipoproteins Human genes 0.000 description 20
- 210000003494 hepatocyte Anatomy 0.000 description 18
- 238000010586 diagram Methods 0.000 description 15
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical group C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 6
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 6
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 229960004586 rosiglitazone Drugs 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 4
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 230000000474 nursing effect Effects 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002213 flavones Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000029052 metamorphosis Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 206010001580 Albuminuria Diseases 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- SYFDWXWLRGHYAJ-HXUWFJFHSA-N Cyclomulberrin Natural products O=C1c2c(O)cc(O)c(C/C=C(\C)/C)c2OC=2c3c(O[C@H](/C=C(\C)/C)C1=2)cc(O)cc3 SYFDWXWLRGHYAJ-HXUWFJFHSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- PWHGUSAQRRPLSJ-IBGZPJMESA-N Isocyclomulberrin Natural products O=C1c2c(O)c(C/C=C(\C)/C)c(O)cc2OC=2c3c(O[C@@H](/C=C(\C)/C)C1=2)cc(O)cc3 PWHGUSAQRRPLSJ-IBGZPJMESA-N 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 1
- 241000219781 Pueraria montana var. lobata Species 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical group O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- SYFDWXWLRGHYAJ-UHFFFAOYSA-N cyclomulberrin Chemical compound C12=CC=C(O)C=C2OC(C=C(C)C)C(C2=O)=C1OC1=C2C(O)=CC(O)=C1CC=C(C)C SYFDWXWLRGHYAJ-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 230000002430 glycogenolytic effect Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- XFFOMNJIDRDDLQ-UHFFFAOYSA-N morusin Chemical compound O1C2=C3C=CC(C)(C)OC3=CC(O)=C2C(=O)C(CC=C(C)C)=C1C1=CC=C(O)C=C1O XFFOMNJIDRDDLQ-UHFFFAOYSA-N 0.000 description 1
- WUBUWBUVAKMGCO-UHFFFAOYSA-N morusin Natural products CC(=CCC1=C(Cc2c3C=CC(C)(C)Oc3cc(O)c2C1=O)c4ccc(O)cc4O)C WUBUWBUVAKMGCO-UHFFFAOYSA-N 0.000 description 1
- XIWCDUHPYMOFIL-UHFFFAOYSA-N mulberrochromene Natural products O1C2=CC=3OC(C)(C)C=CC=3C(O)=C2C(=O)C(CC=C(C)C)=C1C1=CC=C(O)C=C1O XIWCDUHPYMOFIL-UHFFFAOYSA-N 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000012666 negative regulation of transcription by glucose Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229960002800 prednisolone acetate Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 108700022737 rat Fat1 Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a lipid-lowering and liver-protecting composition. The composition contains radix astragali, Kudzuvine roots and white mulberry root bark, and the mass ratio of radix astragali, to Kudzuvine roots to white mulberry root bark is (1-2): (1-2): (0-2). The lipid-lowering and liver-protecting composition can be effectively used for treating obesity-related hyperlipemia and fatty liver, and a remarkable effect is achieved. Besides, the invention discloses a drug containing the lipid-lowering and liver-protecting composition, the drug can be used for effectively treating obesity-related hyperlipemia and fatty liver, and a new choice is provided for treatment of obesity-related hyperlipemia and fatty liver.
Description
Technical field
The present invention relates to a kind of composition and use thereof, especially a kind of have the composition and use thereof reducing obesity-related hyperlipemia with improving fatty liver.
Background technology
The Radix Astragali, have another name called continuous stilbene, its main active is astragaloside, there is suppression metabolism syndrome, delay myocardial ischemia Myocardial pathological changes and improve the effects such as cardiac function, modern medicine study shows, the Radix Astragali has enhancing human body immunity function, protects the liver, diuresis, defying age, anti-stress, blood pressure lowering and wide antibacterial action.Jishengshenqiwan albuminuria can be eliminated, strengthen myocardial contraction, regulate blood sugar content.The Radix Astragali can not only coronary artery dilator, improve blood supply of cardiac muscle, improve immunologic function, and can the process of delaying cell aging.
Radix Puerariae, for the dry root of legume pueraria lobata, habit claims Herba Gelsemii Elegantis.In Radix Puerariae, chief active position is total flavones, and wherein puerarin is one of its main active.Puerarin has blood sugar lowering, blood fat reducing, improves Insulin Resistance; and blood pressure lowering, coronary artery dilator, improve myocardial ischemia, anti-hypoxia reperfusion injury, protection endothelial function to improve hematodinamics, to suppress the multiple cardiovascular protective effect such as platelet aggregation, therefore puerarin is widely used in clinical treatment fro diabetic coronary heart disease and multiple cardiovascular disease.
Cortex Mori is the dry root bark of moraceae plants Mulberry.It is containing flavones ingredient: Sang Su, mulberrochromene, cyclomulberrin etc..Cortex Mori separates and confirms the de-dioxy imido grpup Fructus Vitis viniferae alcohol of blood sugar reducing component and MoranA sugar reducing substance, through overtesting, it has already been proven that the hyperglycemia mice of model induced by alloxan is had dose-dependent hypoglycemic effect by MoranA.
Hyperlipemia, refers to that in blood plasma, lipid concentration exceedes normal range.Blood fat is the general name of contained lipid in human plasma, including cholesterol, triglyceride, cholesterol ester, beta lipoprotein, phospholipid, not esterified fat acid etc..When serum cholesterol exceedes normal value 230 milligrams/100 milliliters, triglyceride more than 140 milligrams/100 milliliters, beta lipoprotein more than 390 milligrams/more than 100 milliliters time, hyperlipidemia can be referred to as.The reason bringing out hyperlipemia is varied.First, gene determines, especially idiopathic hyperlipemia.Second, other diseases secondary, such as obesity, diabetes, Hypothyroidism, nephrotic syndrome and use certain drug etc., all it is likely to bring out hyperlipemia.3rd, smoking, too much edible high glucose and high fat food, can result in cholesterol or triglyceride raises.Obese type hyperlipemia is belonging to the second described above, obesity the hyperlipemia brought out.
Fatty liver, refers to due to the pathological changes that athero in the hepatocyte that a variety of causes causes is too much.The fatty liver difference according to the cause of disease, it is possible to be divided into: obese fatty liver, alcoholic fatty liver, quick weight-lossing fatty liver, dystrophic fatty liver, diabetic fatty liver, Drug fatty liver etc..The health of the positive serious threat compatriots of fatty liver disease, becomes the second largest hepatopathy being only second to viral hepatitis, has been acknowledged as the common cause of disguised liver cirrhosis.
Existing the Radix Astragali, Radix Puerariae and Cortex Mori are combined by certain ratio be used for treating diabetes, hyperlipoproteinemia report, but be used for treating obese type hyperlipemia and fatty liver by the Radix Astragali, Radix Puerariae and Cortex Mori, also do not have any research and report at present.
Summary of the invention
It is an object of the invention to overcome above-mentioned the deficiencies in the prior art part to provide a kind of fat-reducing liver-protecting compositions that can be effective to treatment obese type hyperlipemia and improve fatty liver.Meanwhile, present invention also offers the Preparation method and use of described fat-reducing liver-protecting compositions.
For achieving the above object, the technical scheme that the present invention takes is: a kind of fat-reducing liver-protecting compositions, comprise the Radix Astragali, Radix Puerariae and Cortex Mori, and the mass ratio of the described Radix Astragali, Radix Puerariae and Cortex Mori is the Radix Astragali: Radix Puerariae: Cortex Mori=(1～2): (1～2): (0～2).
Present inventor finds through big quantity research and test, the compositions of the Radix Astragali of special ratios relation described above, Radix Puerariae and Cortex Mori composition, has especially significant effect in dropping obesity-related hyperlipemia and improving fatty liver.
As the preferred implementation of fat-reducing liver-protecting compositions of the present invention, the mass ratio of the described Radix Astragali, Radix Puerariae and Cortex Mori is the Radix Astragali: Radix Puerariae: Cortex Mori=2:1:1.
As the preferred implementation of fat-reducing liver-protecting compositions of the present invention, the mass ratio of the described Radix Astragali, Radix Puerariae and Cortex Mori is the Radix Astragali: Radix Puerariae: Cortex Mori=1:2:1.
As the preferred implementation of fat-reducing liver-protecting compositions of the present invention, the mass ratio of the described Radix Astragali, Radix Puerariae and Cortex Mori is the Radix Astragali: Radix Puerariae: Cortex Mori=1:1:2.
As the preferred implementation of fat-reducing liver-protecting compositions of the present invention, the mass ratio of the described Radix Astragali, Radix Puerariae and Cortex Mori is the Radix Astragali: Radix Puerariae: Cortex Mori=1:1:1.
As the preferred implementation of fat-reducing liver-protecting compositions of the present invention, the mass ratio of the described Radix Astragali, Radix Puerariae and Cortex Mori is the Radix Astragali: Radix Puerariae: Cortex Mori=2:1:0.
Additionally, another object of the present invention is to the preparation method that a kind of fat-reducing liver-protecting compositions as above is provided, for realizing this purpose, the technical scheme that the present invention takes is: the preparation method of a kind of fat-reducing liver-protecting compositions, comprise the following steps: extract with solvent refluxing after the Radix Astragali, Radix Puerariae and Cortex Mori are mixed, recycling design after extraction, and with macroporous resin, extracting solution essence is carried, obtain fat-reducing liver-protecting compositions.
It addition, present invention also offers a kind of medicine for treating obese type hyperlipemia and fatty liver, described pharmaceutical pack is containing fat-reducing liver-protecting compositions as above.
It addition, present invention also offers fat-reducing liver-protecting compositions described above for preparing the purposes in the treatment food of obesity-related hyperlipemia, medicine and health product.
Finally, present invention also offers fat-reducing liver-protecting compositions described above for preparing the purposes in the treatment food of fatty liver, medicine and health product.
Fat-reducing liver-protecting compositions of the present invention, it is possible to be effective to the treatment of obesity-related hyperlipemia and fatty liver, produces significant effect.The present invention contains the medicine of described fat-reducing liver-protecting compositions, it is possible to effectively treatment obese type hyperlipemia and fatty liver, the treatment for obesity-related hyperlipemia and fatty liver provides new selection.
Accompanying drawing explanation
Fig. 1 is for, after the type 2 diabetes mellitus rat of streptozotocin (STZ)-high lipid food (HFD) combined induction is administered 7 weeks, respectively organizing the comparison diagram of fasting glucose.
Fig. 2 is for, after the type 2 diabetes mellitus rat of streptozotocin (STZ)-high lipid food (HFD) combined induction is administered 7 weeks, respectively organizing the comparison diagram of cholesterol.
Fig. 3 is for, after the type 2 diabetes mellitus rat of streptozotocin (STZ)-high lipid food (HFD) combined induction is administered 7 weeks, respectively organizing the comparison diagram of triglyceride.
Fig. 4 is for, after the type 2 diabetes mellitus rat of streptozotocin (STZ)-high lipid food (HFD) combined induction is administered 7 weeks, respectively organizing the comparison diagram of low density lipoprotein, LDL.
Fig. 5 is for, after the type 2 diabetes mellitus rat of streptozotocin (STZ)-high lipid food (HFD) combined induction is administered 12 weeks, respectively organizing the comparison diagram of fasting glucose.
Fig. 6 is for, after the type 2 diabetes mellitus rat of streptozotocin (STZ)-high lipid food (HFD) combined induction is administered 12 weeks, respectively organizing the comparison diagram of cholesterol.
Fig. 7 is for, after the type 2 diabetes mellitus rat of streptozotocin (STZ)-high lipid food (HFD) combined induction is administered 12 weeks, respectively organizing the comparison diagram of triglyceride.
Fig. 8 is for, after the type 2 diabetes mellitus rat of streptozotocin (STZ)-high lipid food (HFD) combined induction is administered 12 weeks, respectively organizing the comparison diagram of glutamate pyruvate transaminase.
Fig. 9 is for, after the type 2 diabetes mellitus rat of streptozotocin (STZ)-high lipid food (HFD) combined induction is administered 12 weeks, respectively organizing the comparison diagram of glutamic oxaloacetic transaminase, GOT.
Figure 10 is for, after the type 2 diabetes mellitus rat of glucocorticoid (GC)+high lipid food combined induction is administered 6 weeks, respectively organizing the comparison diagram of fasting glucose.
Figure 11 is for, after the type 2 diabetes mellitus rat of glucocorticoid (GC)+high lipid food combined induction is administered 6 weeks, respectively organizing the comparison diagram of cholesterol.
Figure 12 is for, after the type 2 diabetes mellitus rat of glucocorticoid (GC)+high lipid food combined induction is administered 6 weeks, respectively organizing the comparison diagram of triglyceride.
Figure 13 is for, after the type 2 diabetes mellitus rat of glucocorticoid (GC)+high lipid food combined induction is administered 10 weeks, respectively organizing the comparison diagram of fasting glucose.
Figure 14 is for, after the type 2 diabetes mellitus rat of glucocorticoid (GC)+high lipid food combined induction is administered 10 weeks, respectively organizing the comparison diagram of cholesterol.
Figure 15 is for, after the type 2 diabetes mellitus rat of glucocorticoid (GC)+high lipid food combined induction is administered 10 weeks, respectively organizing the comparison diagram of triglyceride.
Figure 16 is after the type 2 diabetes mellitus rat to glucocorticoid (GC)+high lipid food combined induction is administered 12 weeks, SD group hepatocyte aspect graph.
Figure 17 is after the type 2 diabetes mellitus rat to glucocorticoid (GC)+high lipid food combined induction is administered 12 weeks, SD+GC group hepatocyte aspect graph.
Figure 18 is after the type 2 diabetes mellitus rat to glucocorticoid (GC)+high lipid food combined induction is administered 12 weeks, HFD group hepatocyte aspect graph.
Figure 19 is after the type 2 diabetes mellitus rat to glucocorticoid (GC)+high lipid food combined induction is administered 12 weeks, HFD+GC group hepatocyte aspect graph.
Figure 20 is after the type 2 diabetes mellitus rat to glucocorticoid (GC)+high lipid food combined induction is administered 12 weeks, rosiglitazone group hepatocyte aspect graph.
Figure 21 is after the type 2 diabetes mellitus rat to glucocorticoid (GC)+high lipid food combined induction is administered 12 weeks, the Radix Astragali: Radix Puerariae: Cortex Mori=2:1:1 group hepatocyte aspect graph.
Figure 22 is after the type 2 diabetes mellitus rat to glucocorticoid (GC)+high lipid food combined induction is administered 12 weeks, the Radix Astragali: Radix Puerariae: Cortex Mori=2:1:0 group hepatocyte aspect graph.
Figure 23 is after the type 2 diabetes mellitus rat to glucocorticoid (GC)+high lipid food combined induction is administered 12 weeks, the Radix Astragali: Radix Puerariae: Cortex Mori=1:2:1 group hepatocyte aspect graph.
Detailed description of the invention
For better illustrating the object, technical solutions and advantages of the present invention, below in conjunction with the drawings and specific embodiments, the invention will be further described.
Embodiment 1
A kind of embodiment of fat-reducing liver-protecting compositions of the present invention, the present embodiment fat-reducing liver-protecting compositions comprises the Radix Astragali, Radix Puerariae and Cortex Mori, and the mass ratio of the described Radix Astragali, Radix Puerariae and Cortex Mori is the Radix Astragali: Radix Puerariae: Cortex Mori=2:1:1.
Embodiment 2
A kind of embodiment of fat-reducing liver-protecting compositions of the present invention, the present embodiment fat-reducing liver-protecting compositions comprises the Radix Astragali, Radix Puerariae and Cortex Mori, and the mass ratio of the described Radix Astragali, Radix Puerariae and Cortex Mori is the Radix Astragali: Radix Puerariae: Cortex Mori=1:2:1.
Embodiment 3
A kind of embodiment of fat-reducing liver-protecting compositions of the present invention, the present embodiment fat-reducing liver-protecting compositions comprises the Radix Astragali, Radix Puerariae and Cortex Mori, and the mass ratio of the described Radix Astragali, Radix Puerariae and Cortex Mori is the Radix Astragali: Radix Puerariae: Cortex Mori=1:1:2.
Embodiment 4
A kind of embodiment of fat-reducing liver-protecting compositions of the present invention, the present embodiment fat-reducing liver-protecting compositions comprises the Radix Astragali, Radix Puerariae and Cortex Mori, and the mass ratio of the described Radix Astragali, Radix Puerariae and Cortex Mori is the Radix Astragali: Radix Puerariae: Cortex Mori=1:1:1.
Embodiment 5
A kind of embodiment of fat-reducing liver-protecting compositions of the present invention, the present embodiment fat-reducing liver-protecting compositions comprises the Radix Astragali, Radix Puerariae and Cortex Mori, and the mass ratio of the described Radix Astragali, Radix Puerariae and Cortex Mori is the Radix Astragali: Radix Puerariae: Cortex Mori=2:1:0.
Embodiment 6 fat-reducing liver-protecting of the present invention compositions fat-reducing liver-protecting effect test
1, fat-reducing liver-protecting compositions of the present invention on streptozotocin (the STZ)-type 2 diabetes mellitus rat fasting blood-glucose of high lipid food (HFD) combined induction, T-CHOL, triglyceride, low density lipoprotein, LDL impact
1.1 test packets
Take male SD rat some, body weight 180～220g, after adaptability raises one week in laboratory conditions, fasting 16h, etherization, take blood in eyeground vein clump, anticoagulant heparin, 4 DEG C centrifugal (3000rpm, 10min) point take blood plasma, and mensuration rat fasting blood-glucose (Glu), triglyceride (TC), T-CHOL (TG) are as the basic biochemistry index of this batch of SD rat.Feeding, after normal feedstuff 1 week, to take 10 and to be only used as normal group, all the other are as model group.After Rat Fast 16h, model group lumbar injection streptozotocin (STZ) solution 35mg/Kg, normal group lumbar injection equal-volume citrate buffer (PH=4.4), volume injected is 5ml/Kg, after injecting 10 days, fasting 16h, eyeground vein clump takes blood, measure fasting glucose FBG, choose FBG the rat of 7.2mmo/L is type 2 diabetes mellitus rat model and gives high lipid food.
Normal rats being taken out 10, for A-normal group, then above-mentioned type 2 diabetes mellitus rat model is randomly divided into 6 groups, often group 8,6 groups are respectively as follows: B-model group；G test group 1；H test group 2；I test group 3；J test group 4；K test group 5.
1.2 dosage are arranged
Present composition dosage is 60g crude drug/day, and the clinical equivalent dosage calculating animal administration according to BioSShi method (animal kg body weight dose factor Commutation Law) is: present composition 7g crude drug/kg.The present composition (Radix Astragali: Radix Puerariae: Cortex Mori) test group 1 (2:1:1)；Test group 2 (1:2:1)；Test group 3 (1:1:2)；Test 4 (1:1:1)；Test group 5 (2:1:0).
G:60g ÷ 60kg × 7 × 20.7875% × 2=2.91025g/Kg, is administered by 10ml/kg；Precision weighs 2.91025g in the Radix Acaciae senegalis of 10ml0.5%；
H:60g ÷ 60kg × 7 × 21.1695% × 2=2.96373g/Kg.It is administered by 10ml/kg；Precision weighs 2.96373g in the Radix Acaciae senegalis of 10ml0.5%；
I:60g ÷ 60kg × 7 × 17.8993% × 2=2.50593g/Kg.It is administered by 10ml/kg；Precision weighs 2.50593g in the Radix Acaciae senegalis of 10ml0.5%；
J:60g ÷ 60kg × 7 × 19.2917% × 2=2.70081g/Kg；It is administered by 10ml/kg；Precision weighs 2.70081g in the Radix Acaciae senegalis of 10ml0.5%；
K:60g ÷ 60kg × 7 × 27.455% × 2=3.8479g/Kg.It is administered by 10ml/kg；Precision weighs 3.8479g in the Radix Acaciae senegalis of 10ml0.5%.
1.3 test methods
Normal group and model group gavage 10% Radix Acaciae senegalis (solvent) respectively, G test group 1, H test group 2, I test group 3, J test group 4, the pharmaceutical composition of K test group 5 gastric infusion embodiment 1～5 respectively is (by the pharmaceutical composition of embodiment 1～5, the Radix Astragali, extract with solvent refluxing after root and Cortex Mori mixing, recycling design after extraction, and with macroporous resin, extracting solution essence is carried rear gastric infusion), each treated animal gastric infusion, once a day, gastric infusion is carried out according to 10ml/Kg/d, the fasting glucose (Glu) of each treated animal after testing respectively after being administered 7 weeks and being administered 12 weeks, triglyceride (TC), cholesterol (TG), low density lipoprotein, LDL (LDL-C).
1.4 result of the tests
1.4.1, after being administered 7 weeks, the fasting glucose (Glu) of each treated animal, triglyceride (TC), cholesterol (TG), low density lipoprotein, LDL (LDL-C) are in shown in Table 1 and accompanying drawing 1～4.
Table 1 be administered Glu, TC, TG, LDL-C result after 7 weeks (N=8)
Compared with normal group,*P < 0.05,**P < 0.01,***P<0.001；Compared with model group,ΔP < 0.05,ΔΔP < 0.01,ΔΔΔP<0.001
By table 1 and accompanying drawing 1～4 it can be seen that compared with normal group, model group blood glucose significantly raises (P < 0.05), it was shown that STZ diabetic mice modeling success.
Impact about on fasting glucose: can be seen that from table 1 and accompanying drawing 1, compared with model group blood glucose, different proportion fat-reducing liver-protecting compositions administration group has significant difference (P < 0.05), has and significantly reduces blood glucose effect；But between each administration group and zero difference.
Impact about on cholesterol: can be seen that from table 1 and accompanying drawing 2, compared with normal group, model group cholesterol significantly raises (P < 0.05)；Compared with model group cholesterol, the different proportion Radix Astragali dissipates administration group and has significant difference (P < 0.05)；K group (2:1:0) has significant difference (P < 0.05) compared with other administration groups；Cholesterol is all had the effect of reduction by each administration group, but K group (2:1:0) relatively other groups are compared the effect reducing cholesterol and become apparent from.
Impact about on triglyceride: from table 2 and accompanying drawing 3, compared with normal group, model group triglyceride significantly raises (P < 0.05)；G (2:1:1), H (1:2:1), J (1:1:1) have significant difference (P < 0.05) compared with model group, it is possible to significantly reduce triglyceride levels.I group does not have significant difference (P > 0.05) compared with model group, it does not have reduce the effect of triglyceride.
Impact about low density lipoprotein, LDL: from table 2 and accompanying drawing 4, compared with normal group, model group low density lipoprotein, LDL significantly raises (P < 0.05)；Compared with model group, each administration group is respectively provided with significant difference (P < 0.05)；K group has significant difference (P < 0.05) compared with other administration groups；The administration group that dissipates the Radix Astragali of different proportion all can reduce low-density lipoprotein white level, but the K group effect that relatively other groups reduce low-density lipoprotein white level becomes apparent from.
Result above shows, the formula of different proportion is different on the impact of blood pressure and blood lipoid.G (2:1:1)；H (1:2:1)；Blood glucose, cholesterol, triglyceride, low density lipoprotein, LDL are all had obvious reduction effect by J (1:1:1).I (1:1:2), K (2:1:0) can reduce the level of cholesterol, low density lipoprotein, LDL, blood glucose, but does not reduce the effect of triglyceride levels.
1.4.2, after being administered 12 weeks, the fasting glucose (Glu) of each treated animal, cholesterol (TG) and triglyceride (TC) are in shown in Table 2 and accompanying drawing 5～7.
Table 2 respectively organize after being administered 12 weeks fasting glucose, cholesterol and triglyceride result (N=8)
Compared with normal group*P < 0.05,**P < 0.01,***P<0.001；Compared with model group,ΔP < 0.05,ΔΔP < 0.01,ΔΔΔP<0.001
Interpretation of result: by table 2 and accompanying drawing 5～7 it can be seen that along with the lengthening of administration time, different proportion compositions difference between the effects in curative effect becomes apparent from.After being administered 12 weeks, H group on blood glucose, cholesterol, triglyceride impact relatively other groups to get well (P < 0.01)；The impact of blood pressure and blood lipoid is taken second place by G group.The advantage that K group reduces cholesterol is comparatively obvious.J group can reduce the level of blood glucose, cholesterol and triglyceride, but its effect relatively other aspects reducing triglyceride to be got well.I group can reduce the level of cholesterol, but the impact of blood pressure and blood lipoid is inconspicuous.
2, the fat-reducing liver-protecting compositions of the present invention impact (on millet straw/glutamate pyruvate transaminase, bilirubinic impact) on type 2 diabetes mellitus rat liver
This test is grouped ibid, tests glutamate pyruvate transaminase (ALT) and the glutamic oxaloacetic transaminase, GOT (AST) of each treated animal after being administered 12 weeks respectively, and test result is in shown in Table 3 and accompanying drawing 8～9.
Table 3 glutamate pyruvate transaminase (ALT) of each group after being administered 12 weeks, glutamic oxaloacetic transaminase, GOT (AST) result (N=8)
Compared with normal group,*P < 0.05,**P < 0.01,***P<0.001；Compared with model group,ΔP < 0.05,ΔΔP < 0.01,ΔΔΔP<0.001
Be can be seen that by table 3 and accompanying drawing 8～9, compared with normal group, the trend that model group glutamic oxaloacetic transaminase, GOT (AST) is increased significantly, but there was no significant difference (P > 0.05)；But compared with model group, the glutamic oxaloacetic transaminase, GOT of each administration group has downward trend.Compared with normal group, model group glutamate pyruvate transaminase is significantly raised, has significant difference (P < 0.05), and after 12 weeks, type 2 diabetes mellitus Liver Function is impaired.Compared with model group, each administration group all significantly reduces glutamic oxaloacetic transaminase, GOT level (P < 0.05), improves liver function；Compared with normal group, each administration group glutamate pyruvate transaminase does not have significant difference (P > 0.05).Therefore deducing that, the present composition of different proportion all can prevent the situation of the abnormal liver function that type 2 diabetes mellitus causes.
Embodiment 7 fat-reducing liver-protecting of the present invention compositions fat-reducing liver-protecting effect test
1, fat-reducing liver-protecting compositions of the present invention on the type 2 diabetes mellitus rat fasting blood-glucose (FPG) of glucocorticoid (GC)+high lipid food combined induction, cholesterol (TC), triglyceride (TG) impact
1.1 test packets
This test is divided into 9 groups, and often group is as follows respectively:
A SD group, N=8
B SD+GC group, N=10
C HFD group, N=8
D HFD+GC group, N=12
E HFD+GC+ rosiglitazone group, N=7
F HFD+GC+ embodiment 1 compositions group, N=9
G HFD+GC+ embodiment 5 compositions group, N=9
I HFD+GC+ embodiment 2 compositions group, N=10
J SD+GC+ embodiment 2 compositions group, N=10
1.2 test methods
SPF rank SD rat, after regular grade Animal House adaptability raises two weeks (about 200-220g), takes hematometry foundation level on an empty stomach.After 3 days, except arm's length basis feedstuff group, all the other are group beginning gavage prednisolone acetate 3.5mg/kg respectively, once a day, starts gastric infusion after 1 hour simultaneously, and high lipid food is fed continuous 12 weeks.At administration 6 weeks and administration 10 weeks, respectively fasting 12h, collect blood and survey the index of each group of fasting glucose, cholesterol, triglyceride, after observing administration 6 weeks and being administered 10 weeks, respectively organize the change of fasting glucose, cholesterol and triglyceride.
1.3 result of the tests
The result of variations of fasting glucose, cholesterol and triglyceride is respectively organized such as shown in accompanying drawing 10～12 after being administered 6 weeks.
Being can be seen that by accompanying drawing 10, from the impact on fasting glucose FPG, model HFD+GC group is compared with arm's length basis group, and blood glucose raises, and has significant difference (P < 0.05).HFD+GC group rat blood sugar is higher than SD+GC group, it may have significant difference (P < 0.05).But SD+GC and SD group compares blood glucose without rising, it was shown that normal feedstuff combination with glucocorticoids modeling is unsuccessful when 6 weeks, but high fat combination with glucocorticoids modeling success.Compared with model HFD+GC group, rosiglitazone group rat blood sugar reduces, and has significant difference (P < 0.05).Now, the J group that only basis is fed is compared with model group, blood glucose reduces, there is hypoglycemic activity, impact in combination with body weight, find that the J group blood glucose feeding normal feedstuff is lower than F, G, I group feeding high lipid food, body weight also corresponding lower than, point out the present composition that body weight inhibitory action is probably the reason of blood sugar lowering.
Being can be seen that by accompanying drawing 11, from the impact on cholesterol TC, model HFD+GC group is compared with arm's length basis group, and cholesterol raises, and has significant difference (P < 0.01).Each administration group all can reduce cholesterol, and the amplitude of the J group cholesterol reducing of basis nursing is bigger.
Be can be seen that by accompanying drawing 12, from the impact on triglyceride TG, the triglyceride levels of model group does not all raise compared with normal group, high fat nursing group HFD group triglyceride levels is minimum curiously, showing that in diabetes model blood plasma, triglyceride levels is to reduce, this awaits further looking at and thinking deeply.
The result of variations of fasting glucose, cholesterol and triglyceride is respectively organized such as shown in accompanying drawing 13～15 after being administered 10 weeks.
Being can be seen that by accompanying drawing 13, the impact from fasting glucose FPG: compared with normal group, SD+GC, HFD, HFD+GC model group blood glucose all raises, and HFD+GC model group blood glucose is the highest, has significant difference.Its reason is in that glucocorticoid belongs to insulin resistance hormone, it is possible to strengthen the gluconeogenesis in liver, promotes hepatic glycogenolytic, it is suppressed that peripheral tissues is to the picked-up of glucose and utilization, thus causing that blood glucose raises.Compared with HFD+GC model group, rosiglitazone group rat blood sugar reduces, and has significant difference (P < 0.001).The each administration group blood glucose of the present composition is significantly reduced, having significant difference, and J group compares other groups, blood sugar lowering amplitude becomes apparent from, reduce the impact of body weight in combination with the former side of J group, body weight inhibitory action is probably the reason of blood sugar lowering by the prompting present composition.
Being can be seen that by accompanying drawing 14, from the impact on cholesterol TC, model HFD, HFD+GC group is compared with arm's length basis group, and cholesterol raises, and has significant difference (P < 0.01).Each administration group all can reduce cholesterol, and the amplitude of F, G, I group cholesterol reducing that the J group fed of basis, high fat are fed is bigger.
Being can be seen that by accompanying drawing 15, from the impact on triglyceride TG, the triglyceride levels of model group does not all raise compared with normal group, and high fat nursing group HFD group triglyceride levels is minimum curiously, and the situation of change that this and early stage are administered 6 weeks is basically identical.
2, the fat-reducing liver-protecting compositions of the present invention impact on the type 2 diabetes mellitus Murine Stem metamorphosis of glucocorticoid (GC)+high lipid food combined induction
To A, B, C, D, E, F, G, I group after being administered 12 weeks in above-mentioned 1, adopt H-E staining, under the same visual field, observe the metamorphosis of each group of rat liver cells.Observed result is such as shown in accompanying drawing 16～23.
Being can be seen that by accompanying drawing 16～23, the visible lobules of liver of normal SD group rat, in lobule, the liver in visible central artery and around hepatocyte besieged city is hardened structure, has no obvious pathological change.Having a small amount of hepatocyte Minimal fatty degeneration in the visible lobules of liver of SD+GC group rat, in hepatocyte, visible small fat drips.In HFD and the HFD+GC group visible lobules of liver of rat, in hepatocyte, steatosis is obvious, is filled with vesicle sample fat and drips in hepatocyte.Having point-like necrotic zone in lobule as seen, visible inflammatory cell infiltration, and HFD+GC group rat fat degeneration around becomes apparent from.Compared with HFD+GC group rat, rosiglitazone group, F group, the visible hepatic cell fattydegeneration of I group rat are few, and in hepatocyte, rare vesicle sample fat drips.And the visible hepatic cell fattydegeneration of G group rat is obvious, fat vacuole big as seen in hepatocyte.
Finally be should be noted that; above example is only in order to illustrate technical scheme but not limiting the scope of the invention; although the present invention being explained in detail with reference to preferred embodiment; it will be understood by those within the art that; technical scheme can be modified or equivalent replacement, without deviating from the spirit and scope of technical solution of the present invention.
Claims (10)
1. a fat-reducing liver-protecting compositions, it is characterised in that comprise the Radix Astragali, Radix Puerariae and Cortex Mori, and the mass ratio of the described Radix Astragali, Radix Puerariae and Cortex Mori is the Radix Astragali: Radix Puerariae: Cortex Mori=(1～2): (1～2): (0～2).
2. fat-reducing liver-protecting compositions as claimed in claim 1, it is characterised in that the mass ratio of the described Radix Astragali, Radix Puerariae and Cortex Mori is the Radix Astragali: Radix Puerariae: Cortex Mori=2:1:1.
3. fat-reducing liver-protecting compositions as claimed in claim 1, it is characterised in that the mass ratio of the described Radix Astragali, Radix Puerariae and Cortex Mori is the Radix Astragali: Radix Puerariae: Cortex Mori=1:2:1.
4. fat-reducing liver-protecting compositions as claimed in claim 1, it is characterised in that the mass ratio of the described Radix Astragali, Radix Puerariae and Cortex Mori is the Radix Astragali: Radix Puerariae: Cortex Mori=1:1:2.
5. fat-reducing liver-protecting compositions as claimed in claim 1, it is characterised in that the mass ratio of the described Radix Astragali, Radix Puerariae and Cortex Mori is the Radix Astragali: Radix Puerariae: Cortex Mori=1:1:1.
6. fat-reducing liver-protecting compositions as claimed in claim 1, it is characterised in that the mass ratio of the described Radix Astragali, Radix Puerariae and Cortex Mori is the Radix Astragali: Radix Puerariae: Cortex Mori=2:1:0.
7. the preparation method of the fat-reducing liver-protecting compositions as described in any one of claim 1～6, it is characterized in that, comprise the following steps: extract with solvent refluxing after the Radix Astragali, Radix Puerariae and Cortex Mori are mixed, recycling design after extraction, and with macroporous resin, extracting solution essence is carried, obtain fat-reducing liver-protecting compositions.
8. the medicine being used for treating obesity-related hyperlipemia and fatty liver, it is characterised in that comprise the fat-reducing liver-protecting compositions as described in any one of claim 1～6.
9. the fat-reducing liver-protecting compositions as described in any one of claim 1～6 is for preparing the purposes in the treatment food of obesity-related hyperlipemia, medicine and health product.
10. the fat-reducing liver-protecting compositions as described in any one of claim 1～6 is for preparing the purposes in the treatment food of fatty liver, medicine and health product.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610245139.1A CN105726638A (en) | 2016-04-19 | 2016-04-19 | Lipid-lowering and liver-protecting composition and application thereof |
| PCT/CN2017/079796 WO2017181857A1 (en) | 2016-04-19 | 2017-04-07 | Composition for fat reduction and liver protection, and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610245139.1A CN105726638A (en) | 2016-04-19 | 2016-04-19 | Lipid-lowering and liver-protecting composition and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105726638A true CN105726638A (en) | 2016-07-06 |
Family
ID=56254835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610245139.1A Pending CN105726638A (en) | 2016-04-19 | 2016-04-19 | Lipid-lowering and liver-protecting composition and application thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN105726638A (en) |
| WO (1) | WO2017181857A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106924349A (en) * | 2017-03-08 | 2017-07-07 | 北京宜生堂医药科技研究有限公司 | A kind of isopentene group flavonoid extract, its preparation method and application |
| WO2017181857A1 (en) * | 2016-04-19 | 2017-10-26 | 北京宜生堂医药科技研究有限公司 | Composition for fat reduction and liver protection, and application thereof |
| CN107854522A (en) * | 2017-09-13 | 2018-03-30 | 北京宜生堂医药科技研究有限公司 | A kind of composition and its production and use |
| WO2018202107A1 (en) * | 2017-05-05 | 2018-11-08 | 中国科学院上海药物研究所 | Pharmaceutical composition for treating hyperlipidemia and atherosclerosis |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102688295A (en) * | 2012-06-14 | 2012-09-26 | 上海中医药大学 | Chinese medicine composition for controlling metabolic diseases as well as preparation method and application thereof |
| CN102846715A (en) * | 2011-06-29 | 2013-01-02 | 包头市千年健药物研究开发有限公司 | Pharmaceutical formulation for treating diabetes complicated with hyperlipoproteinemia |
| CN104013696A (en) * | 2014-06-18 | 2014-09-03 | 上海中医药大学 | Plant medicine composition for preventing and treating metabolic syndrome and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105726638A (en) * | 2016-04-19 | 2016-07-06 | 北京宜生堂医药科技研究有限公司 | Lipid-lowering and liver-protecting composition and application thereof |
-
2016
- 2016-04-19 CN CN201610245139.1A patent/CN105726638A/en active Pending
-
2017
- 2017-04-07 WO PCT/CN2017/079796 patent/WO2017181857A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102846715A (en) * | 2011-06-29 | 2013-01-02 | 包头市千年健药物研究开发有限公司 | Pharmaceutical formulation for treating diabetes complicated with hyperlipoproteinemia |
| CN102688295A (en) * | 2012-06-14 | 2012-09-26 | 上海中医药大学 | Chinese medicine composition for controlling metabolic diseases as well as preparation method and application thereof |
| CN104013696A (en) * | 2014-06-18 | 2014-09-03 | 上海中医药大学 | Plant medicine composition for preventing and treating metabolic syndrome and application thereof |
Non-Patent Citations (6)
| Title |
|---|
| 刘永录等: "葛根保健作用的化学及药理学基础研究近况", 《河北中医》 * |
| 童红莉等: "黄芪多糖对高脂血症大鼠血脂的调节", 《中国临床康复》 * |
| 缪亚东等: "正交试验优选葛根、山楂降脂有效部位的纯化工艺", 《中国药房》 * |
| 郑培永等: "葛根素对非酒精性脂肪肝大鼠肝脏脂质的影响", 《上海中医药杂志》 * |
| 黄翠立: "不同剂量葛根煎剂对高脂血症患者血脂的影响", 《河北中医》 * |
| 黄翠立等: "不同剂量葛根煎剂对高脂血症患者血脂及IL-6的影响", 《辽宁中医药大学学报》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017181857A1 (en) * | 2016-04-19 | 2017-10-26 | 北京宜生堂医药科技研究有限公司 | Composition for fat reduction and liver protection, and application thereof |
| CN106924349A (en) * | 2017-03-08 | 2017-07-07 | 北京宜生堂医药科技研究有限公司 | A kind of isopentene group flavonoid extract, its preparation method and application |
| WO2018202107A1 (en) * | 2017-05-05 | 2018-11-08 | 中国科学院上海药物研究所 | Pharmaceutical composition for treating hyperlipidemia and atherosclerosis |
| CN108785370A (en) * | 2017-05-05 | 2018-11-13 | 中国科学院上海药物研究所 | A kind of pharmaceutical composition for treating hyperlipemia and atherosclerosis |
| CN107854522A (en) * | 2017-09-13 | 2018-03-30 | 北京宜生堂医药科技研究有限公司 | A kind of composition and its production and use |
| CN107854522B (en) * | 2017-09-13 | 2020-10-30 | 北京宜生堂医药科技研究有限公司 | Composition and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017181857A1 (en) | 2017-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105726638A (en) | Lipid-lowering and liver-protecting composition and application thereof | |
| US10960044B2 (en) | Powder formulation having hypoglycemic and hypolipidemic functions and method for preparing the same | |
| CN102133221B (en) | Compound traditional Chinese medicine extract preventing glucose metabolism disturbance and preparation method thereof | |
| CN102526479A (en) | Health-care medicine formula with functions of enhancing immunity and lowering blood sugar | |
| CN103301205A (en) | Refined glossy privet fruit total glycosides capable of preventing and treating liver injury, preparation method and application thereof | |
| CN103585245B (en) | Preparation method, extract and its application of common pratia herb extract | |
| CN107468683A (en) | The purposes of alantolactone and its derivative in fatty hepatic injury is prevented and treated | |
| CN103800352B (en) | Compound traditional Chinese medicinal effective component preparation for resisting alcoholic fatty liver disease and application thereof | |
| CN109954024B (en) | A fructus Syzygii Aromaticae effective part, its preparation method and application in preparing medicine or food with blood sugar lowering effect | |
| CN109394839B (en) | A semen Syzygii Aromatici extract with blood sugar or blood lipid lowering effect, and its preparation method and application | |
| CN101890073B (en) | Chinese medicinal composition for preventing and treating hyperlipaemia and fatty liver and preparation method thereof | |
| CN106074671A (en) | U.S. rattan fruit leaf extract application in preparing hypoglycemic drug | |
| CN105106300A (en) | Use of cyclocarya paliurus extract in preparation of drug for preventing and treating non-alcoholic fatty liver disease | |
| CN100464755C (en) | Traditional Chinese medicine preparation with functions of immunological regulation for anti-chemical damage | |
| CN102861278B (en) | Lipid-lowering extract from effective parts of sharpleaf galangal fruit and preparation and application thereof | |
| CN103285113B (en) | Pharmaceutical composition for preventing and/or treating diabetes mellitus | |
| CN101664423A (en) | Hypoglycemic active part of osmanthus fragrans, preparation method and application thereof | |
| CN101269152A (en) | Application of matrimony vine and black fungus in preparing fatty liver resistant medicament | |
| CN115317534B (en) | Application of myrtle extract in reducing blood sugar and treating diabetic nephropathy | |
| CN105535866A (en) | Medicine for treating hyperlipidemia and preparation method thereof | |
| CN109966283A (en) | Application of the degreasing cinnamon polyphenol extract in preparation prevention and treatment diabetic nephropathy product | |
| CN110638856A (en) | Medicine for preventing or reversing primary hypertension, type 2 diabetes or homologous diseases and animal model construction method | |
| CN104055115A (en) | Health care product containing Maca, Dendrobium and Rhizoma Panacis Majoris and preparation method thereof | |
| CN101322762B (en) | Medicinal composition for treating diabetes | |
| CN102028725B (en) | Traditional Chinese medicine composition, extract, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160706 |